

## DOCTORAL THESIS

### Development of a targeted liposomal delivery system for encapsulated cantharidin to treat hepatocellular carcinoma

Zhang, Xue

*Date of Award:*  
2017

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

## ABSTRACT

**Background:** Despite increasing incidence and morbidity globally, hepatocellular carcinoma (HCC) remains a big challenge clinically. The difficulty to treat HCC is largely due to non-specific chemotherapy causing life-threatening toxicity and severe drug-related adverse effects. Extensive studies on targeted drug delivery systems (DDS) have revealed a great potential in specific delivery of chemotherapeutics for cancer treatment, which should be a way to overcome the limitations of conventional chemotherapy.

Cantharidin (CTD) is a natural product from Chinese medicine showing a great potency but narrow therapeutic window with high toxicity. Its therapeutic potential is proposed to be improved with nanoliposomal encapsulation. To explore the potential of this liposomal delivery system for HCC treatment, in this study we developed and characterized liposomal carriers with CTD encapsulated and liposomal surface modified for targeted delivery to the HCC models *in vitro* and *in vivo*.

**Methods:** In the present study, liposomal delivery system was developed with cantharidin (CTD) encapsulated as anticancer assembly for HCC treatment. Firstly, in order to demonstrate the feasibility of liposomal encapsulation for CTD, the plain liposomal CTD was prepared and the anticancer effects were evaluated *in vitro* and *in vivo* with comparison to the free CTD formulation (Chapter 2). Then, to achieve specific penetrability of the liposomal CTD for HCC, it was further modified with a cancer cell specific penetrating peptide BR2, and its superior penetrability was evaluated on both *in vitro* monolayer and 3D HepG2 cells including MTT assay, cellular uptake, internalization, tumor spheroid penetration and inhibition, and *in vivo* subcutaneous HCC mice model (Chapter 3). Finally, the dual-functionalized liposomes with BR2 and anti-carbonic anhydrase IX (CA IX) antibody were achieved for more efficient delivery with specific penetrating and targeting properties on orthotopic HCC model (Chapter 4).

**Results:** The key results of the study are: (1) liposomal CTD can augment the anti-proliferative effects of CTD, and enhance the anticancer efficacy on subcutaneous HepG2-bearing nude mice, which might be due to the enhanced solubility of the drug as well as intracellular delivery (Chapter 2); (2) with BR2 penetrating peptide modification, the liposomal CTD can get into cancerous cells specifically and penetrate deeper in 3D tumor models. A better tumor growth inhibition was also seen in the subcutaneous HCC mice of BR2-modified liposomes treatment than that of the other group, which could be contributed to the passive targeting of liposomes as well as the specific penetrating properties induced by BR2 peptide (Chapter 3); (3) the dual-functionalized liposomes with BR2 peptide and anti-CA IX antibody modification can enhance the drug internalization into HepG2 cells and further improve the anticancer efficacy of drugs compared to other formulations on orthotopic HCC nude mice (Chapter 4).

**Conclusion:** These results demonstrate 1) the liposomal delivery system as a powerful tool to improve anticancer effects of chemotherapeutic agent; 2) the usefulness of BR2 and CA IX modified-liposomal nano-delivery of CTD and their combination might be a potential modality for HCC treatment. The study paved a way for clinical translational medicine of this ligands-modified liposomal delivery system for targeted treatment of HCC.

## TABLE OF CONTENTS

<b>DECLARATION</b> .....	i
<b>ABSTRACT</b> .....	ii
<b>ACKNOWLEDGEMENTS</b> .....	iv
<b>TABLE OF CONTENTS</b> .....	v
<b>LIST OF FIGURES</b> .....	xi
<b>LIST OF TABLES</b> .....	xv
<b>LIST OF ABBREVIATIONS</b> .....	xvi
<b>CHAPTER 1 Background and Literature Review</b> .....	1
<b>1.1 Hepatocellular carcinoma</b> .....	2
1.1.1 Epidemiology of hepatocellular carcinoma (HCC).....	2
1.1.2 Therapeutic modalities of HCC.....	4
1.1.3 Challenges of current HCC treatment .....	8
<b>1.2 Liposome as an effective tool for cancer therapeutics delivery</b> .....	9
1.2.1 General knowledge about liposomes.....	9
1.2.2 Liposomes encapsulation improves anticancer properties of drugs .....	12
1.2.3 Liposomes modification endows themselves beneficial targeting properties .....	13
1.2.4 Challenges for the liposomal cancer treatment .....	18
<b>1.3 Designing principles of ‘SMART’ liposomal delivery systems for HCC</b> .....	21
1.3.1 Selection of targeting ligand—BR2 peptide as an example.....	23

1.3.2 Selection of targeting receptor—CA IX as an example .....	24
1.3.3 Selection of chemotherapeutic agents—cantharidin as an example .....	30
<b>1.4 Experimental use of liposomes for HCC treatment .....</b>	<b>37</b>
<b>1.5 Objectives of the study .....</b>	<b>39</b>
<b>CHAPTER 2 Liposomes Encapsulation Augments Anticancer Effects of CTD against HCC .....</b>	<b>41</b>
<b>2.1 Introduction .....</b>	<b>42</b>
<b>2.2 Experimental details.....</b>	<b>43</b>
2.2.1 Materials.....	43
2.2.2 Liposomal CTD preparation and characterization .....	44
2.2.2.1 Preparation and characterization of liposomal CTD.....	44
2.2.2.2 Quantitative analysis and estimation of drug entrapment.....	45
2.2.3 <i>In vitro</i> anticancer effects of liposomal CTD .....	48
2.2.3.1 MTT cell proliferation assay.....	48
2.2.3.2 Morphology observation of HepG2 cells after treatment .....	49
2.2.3.3 Cell cycle analysis .....	49
2.2.3.4 Annexin V/PI apoptosis analysis .....	50
2.2.4 <i>In vivo</i> anticancer effects of liposomal CTD.....	51
2.2.5 Statistical analysis .....	51
<b>2.3 Results and Discussion .....</b>	<b>52</b>
2.3.1 Preparation and characterization of liposomal CTD .....	52
2.3.2 Augmented anticancer effects of liposomal CTD <i>in vitro</i> .....	55
2.3.2.1 Anti-proliferative effects of liposomal CTD on HepG2 cells.....	55
2.3.2.2 Cell and nuclear morphology changes.....	57

2.3.2.3	Cell cycle arrested at G2/M phase .....	59
2.3.2.4	Apoptosis induced by liposomal CTD.....	61
2.3.3	Enhanced therapeutic efficacy of liposomal CTD <i>in vivo</i> .....	63
<b>2.4</b>	<b>General Conclusion .....</b>	<b>67</b>
<b>CHAPTER 3 BR2 Penetrating Peptide Modified Liposomal CTD Enhances Chemotherapeutic Effects of CTD against HCC .....</b>		<b>69</b>
<b>3.1</b>	<b>Introduction .....</b>	<b>70</b>
<b>3.2</b>	<b>Experimental details.....</b>	<b>72</b>
3.2.1	Materials.....	72
3.2.2	Preparation and Characterization of BR2-modified liposomes.....	73
3.2.2.1	Synthesis of DSPE-PEG-BR2 .....	73
3.2.2.2	Preparation of BR2 modified liposomes.....	74
3.2.2.3	Optimization of BR2 molar ratios for modification .....	75
3.2.2.4	Particle size characterization .....	75
3.2.2.5	Serum stability .....	75
3.2.2.6	<i>In vitro</i> drug release .....	76
3.2.3	<i>In vitro</i> evaluation of BR2-modified liposomes on monolayer HepG2 .....	77
3.2.3.1	Cytotoxicity studies .....	77
3.2.3.2	Cellular uptake of liposomes .....	78
3.2.3.3	Internalization of BR2-Lp in HepG2 cells.....	79
3.2.4	<i>In vitro</i> evaluation of BR2-modified liposomes on 3D HepG2 .....	79
3.2.4.1	Establishment of 3D HepG2 tumor spheroid.....	79
3.2.4.2	Tumor spheroid penetration study .....	80
3.2.4.3	Tumor spheroid inhibition study.....	80
3.2.5	<i>In vivo</i> evaluation of BR2-modified liposomes.....	81

3.2.5.1	Animals and subcutaneous HCC model .....	81
3.2.5.2	<i>In vivo</i> real-time fluorescence imaging.....	82
3.2.5.3	<i>In vivo</i> anticancer efficacy .....	82
3.2.6	Statistics analysis.....	83
<b>3.3</b>	<b>Results and Discussion .....</b>	<b>84</b>
3.3.1	BR2-modified liposomes preparation and characterization .....	84
3.3.1.1	Successful synthesis of DSPE-PEG-BR2 .....	84
3.3.1.2	2% BR2 molar ratio for liposomes modification.....	86
3.3.1.3	Particle size of BR2-modified liposomes .....	88
3.3.1.4	Serum stability and sustained drug release .....	89
3.3.2	<i>In vitro</i> evaluation of BR2-modified liposomes on monolayer HepG2 .....	91
3.3.2.1	Cytotoxicity studies .....	91
3.3.2.2	Different cellular uptake of BR2-Lp <i>in vitro</i> .....	94
3.3.2.3	Cellular internalization of BR2-Lp in HepG2 cell.....	96
3.3.3	<i>In vitro</i> evaluation of BR2-modified liposomes on 3D HepG2 .....	97
3.3.3.1	HepG2 3D tumor spheroid formation.....	97
3.3.3.2	Tumor spheroid penetration.....	98
3.3.3.3	Tumor spheroids inhibition.....	100
3.3.4	<i>In vivo</i> evaluation of BR2-modified liposomes.....	103
3.3.4.1	<i>In vivo</i> targeting efficiency and biodistribution.....	103
3.3.4.2	<i>In vivo</i> anticancer efficacy .....	105
<b>3.4</b>	<b>Discussion .....</b>	<b>107</b>
<b>3.5</b>	<b>General conclusion .....</b>	<b>111</b>
 <b>CHAPTER 4 Dual-functionalized Liposomes with BR2 Peptide and CA IX</b>		
	<b>Antibody for Targeted Treatment of HCC .....</b>	<b>112</b>

<b>4.1 Introduction</b> .....	113
<b>4.2 Experimental details</b> .....	115
4.2.1 Materials .....	115
4.2.2 Preparation and characterization of different liposomes .....	116
4.2.2.1 Synthesis of DSPE-PEG-BR2 .....	116
4.2.2.2 Synthesis of DSPE-PEG-CA IX .....	116
4.2.2.3 Different liposomes preparation .....	117
4.2.2.4 Particle size characterization of liposomes .....	119
4.2.3 <i>In vitro</i> cell proliferation study .....	119
4.2.4 Cellular internalization by confocal fluorescent microscopy .....	120
4.2.5 Specific cell-associated binding study of DF-Lp <i>in vitro</i> .....	121
4.2.5.1 Induction of CA IX antigen expression <i>in vitro</i> .....	121
4.2.5.2 Cellular binding studies on DF-Lp .....	122
4.2.5.3 Competition assay of DF-Lp.....	122
4.2.6 <i>In vivo</i> anticancer efficacy of DF-Lp evaluation.....	123
4.2.6.1 Luciferase activity of the transfected HepG2-Red-FLuc cells .....	123
4.2.6.2 Establishment of orthotopic HCC models .....	123
4.2.6.3 <i>In vivo</i> accumulation of DiR-labeled DF-Lp .....	124
4.2.6.4 <i>In vivo</i> anticancer efficacy of the DF-Lp/CTD .....	124
4.2.7 Statistical analysis .....	125
<b>4.3 Results and discussion</b> .....	126
4.3.1 Preparation and characterization of dual-functionalized liposomes (DF-Lp) .....	126
4.3.2 <i>In vitro</i> evaluation of the DF-Lp .....	129



4.3.2.1	Enhanced anti-proliferative effects of DF-Lp.....	129
4.3.2.2	Internalization of NBD-DPPE labeled DF-Lp.....	131
4.3.2.3	Colocalization of DF-Lp by confocal microscopy .....	132
4.3.3	Specific cell binding of DF-Lp to CA IX positive cells.....	134
4.3.4	<i>In vivo</i> anticancer effects of DF-Lp on orthotopic HCC mice .....	136
4.3.4.1	Establishment of orthotopic HCC model.....	136
4.3.4.2	<i>In vivo</i> tumor accumulation of DF-Lp .....	138
4.3.4.3	<i>In vivo</i> anticancer effect of DF-Lp on orthotopic HCC mice .....	139
<b>4.4</b>	<b>General conclusion .....</b>	<b>141</b>
	<b>CHAPTER 5 Overall Conclusion and Future Prospects .....</b>	<b>143</b>
<b>5.1</b>	<b>Overall conclusion for the study .....</b>	<b>144</b>
<b>5.2</b>	<b>Prospective for future studies.....</b>	<b>149</b>
	<b>PUBLICATIONS .....</b>	<b>152</b>
	<b>CONFERENCE PRESENTATIONS.....</b>	<b>154</b>
	<b>LIST OF REFERENCES .....</b>	<b>155</b>
	<b>CURRICULUM VITAE.....</b>	<b>180</b>